Next generation of antibody-based therapeutics (CmAbs)
ImmunGene's technology empowers monoclonal antibodies targeted to tumor cells by fusing them to immune effector molecule(s) e.g. cytokine, chemokine and co-stimulatory molecule(s), thereby combining the specificity of antibodies with the potent anti-tumor effects of immune effector molecule. Our antibody-fusion proteins are designed to be stable in the bloodstream and efficiently target cancer cells. This approach allows sparing non-targeted cells and thus reducing many of the toxic effects of traditional immune effector molecules while enhancing the antitumor activity of the antibody. Our lead antibody-fusion molecule uses IFNa effector cytokine.
Stand alone targeted cytotoxic therapy and optimized immune cell mediated attack against tumor killing.
ANTIBODY-FUSION MOLECULE MECHANISM OF ACTION
Quick fact about CmAbs
♦ CmAb - Antibody fused with immune effector molecule
♦ CmAb MW ranges 160-180 kDa compared to ~150 kDa of mAb
♦ CmAb is genetically engineered molecule
- no chemical conjugation
- homogenous single step production
♦ Cytokine/chemokine fusion does NOT create steric hindrance with Fc and antigen binding
- intact ADCC and CDC functions
♦ CmAb are manufactured in mAb producing commercial cell lines
♦ CmAb platform offers a unique competitive advantage against unconjugated and conjugated antibodies in a highly competitive market
♦ Potentially low COGS